13F Holdings
中文EN

PTN PALATIN TECHNOLOGIES INC

Pharmaceutical Preparations · Nasdaq · SEC CIK 911216 · Fiscal year ends 06/30

Financial factors as of 2026-09-30 (2027Q1), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-276.9%
TTM EPS YoY-4.0%
Revenue 3-yr CAGR-61.6%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-5,354.1%
Net margin-5,261.5%
FCF margin—
EBITDA margin-5,335.2%

Returns

ROE-1,495.4%
ROA-271.7%
ROIC (approx.)—
Asset turnover0.05x

Leverage & solvency

Liabilities / assets57.1%
Debt / equity0.00x
Current ratio1.67x
Interest coverage-2,873.67x

Cash quality & payout

Operating cash flow / net income0.86x
Accruals ratio-36.9%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20262026-06-30FY20252025-06-30FY20242024-06-30FY20232023-06-30FY20222022-06-30
Income statement
Revenue$8.83M$0$4.49M$4.85M$1.47M
Cost of revenue——$97,637$418,470$217,529
Gross profit——$4.39M$4.44M$1.25M
R&D expense$12.37M$14.90M$22.40M$22.63M$21.33M
SG&A expense$9.48M$7.81M$12.27M$15.29M$16.51M
Operating income-$8.67M-$17.46M-$22.50M-$32.46M-$36.59M
Interest expense$6,726$15,025$17,114$20,013$29,682
Pretax income———-$32.22M-$36.20M
Income tax-$8.38M-$17.31M-$29.74M-$4.67M$0
Net income-$8.38M-$17.31M-$29.74M-$24.04M-$36.20M
EBITDA-$8.61M-$17.20M-$22.16M-$32.17M-$36.46M
EPS (basic)-2.96-32.15-2.02-2.21—
EPS (diluted)-2.96-32.15-101.16——
Weighted avg. shares (diluted)2.83M538,348293,951——
Balance sheet
Cash & equivalents$7.49M$9.53M$9.53M$7.99M$29.94M
Short-term investments——$0$2.99M$0
Receivables$300,770$0$0$2.92M$1.78M
Inventory——$0$526,000$944,471
Current assets$8.16M$2.92M$9.77M$16.32M$34.60M
PP&E, net$118,064$129,444$388,361$684,910$539,314
Total assets$8.52M$3.27M$10.74M$17.94M$36.07M
Current liabilities$1.77M$8.01M$9.66M$15.13M$16.26M
Total liabilities$1.84M$8.04M$10.85M$19.66M$19.80M
Shareholders' equity$6.69M-$4.78M-$111,497-$1.98M$16.27M
Shares outstanding1.78M929,597358,53211.66M9.27M
Cash flow statement
Operating cash flow-$13.53M-$21.31M-$31.46M-$29.27M-$29.92M
Capital expenditure$51,299$0$42,526$433,927$261,374
Free cash flow-$13.58M-$21.31M-$31.50M-$29.71M-$30.18M
Investing cash flow-$51,299$3.13M$12.45M-$3.43M-$261,374
Financing cash flow$18.51M$11.21M$20.55M$10.75M$18,358
Depreciation & amortization$62,679$258,917$339,075$288,331$126,668
Stock-based compensation$1.33M$1.38M$1.87M$1.67M$2.51M

Free plan shows the latest 5 periods; Pro shows all 17 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.